These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 20170207)

  • 1. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
    Johnson TN; Boussery K; Rowland-Yeo K; Tucker GT; Rostami-Hodjegan A
    Clin Pharmacokinet; 2010 Mar; 49(3):189-206. PubMed ID: 20170207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
    Ghobadi C; Johnson TN; Aarabi M; Almond LM; Allabi AC; Rowland-Yeo K; Jamei M; Rostami-Hodjegan A
    Clin Pharmacokinet; 2011 Dec; 50(12):809-22. PubMed ID: 22087867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling Factors for Clearance in Adult Liver Cirrhosis.
    El-Khateeb E; Achour B; Scotcher D; Al-Majdoub ZM; Athwal V; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2020 Dec; 48(12):1271-1282. PubMed ID: 32978222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
    Barter ZE; Tucker GT; Rowland-Yeo K
    Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling.
    Shiran MR; Proctor NJ; Howgate EM; Rowland-Yeo K; Tucker GT; Rostami-Hodjegan A
    Xenobiotica; 2006 Jul; 36(7):567-80. PubMed ID: 16864504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
    McGinnity DF; Waters NJ; Tucker J; Riley RJ
    Drug Metab Dispos; 2008 Jun; 36(6):1126-34. PubMed ID: 18356267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
    Lammers LA; Achterbergh R; van Schaik RHN; Romijn JA; Mathôt RAA
    Clin Pharmacokinet; 2017 Oct; 56(10):1231-1244. PubMed ID: 28229374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.
    Johnson TN; Rostami-Hodjegan A; Tucker GT
    Clin Pharmacokinet; 2006; 45(9):931-56. PubMed ID: 16928154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
    Rasool MF; Khalil F; Läer S
    Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences.
    Inoue S; Howgate EM; Rowland-Yeo K; Shimada T; Yamazaki H; Tucker GT; Rostami-Hodjegan A
    Xenobiotica; 2006 Jun; 36(6):499-513. PubMed ID: 16865818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay.
    Kosugi Y; Hosea N
    Mol Pharm; 2020 Jul; 17(7):2299-2309. PubMed ID: 32478525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
    Rasool MF; Khalil F; Läer S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
    Shida S; Utoh M; Murayama N; Shimizu M; Uno Y; Yamazaki H
    Xenobiotica; 2015; 45(10):881-6. PubMed ID: 26075833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of in vivo rat biliary drug clearance from an in vitro hepatocyte efflux model.
    Lundquist P; Lööf J; Fagerholm U; Sjögren I; Johansson J; Briem S; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):459-68. PubMed ID: 24396143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake.
    Fujino R; Hashizume K; Aoyama S; Maeda K; Ito K; Toshimoto K; Lee W; Ninomiya SI; Sugiyama Y
    Eur J Pharm Sci; 2018 Dec; 125():181-192. PubMed ID: 30287410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
    Plowchalk DR; Rowland Yeo K
    Eur J Clin Pharmacol; 2012 Jun; 68(6):951-60. PubMed ID: 22258279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.